Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.

Advertisement

Related Content

Pfizer Seizes Long-Term Immuno-Oncology Opportunity With Merck Deal
Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
Merck KGAA Begins Transformation Effort By Closing Geneva Site
Deals of the Week: Stada/Grunenthal, Stada/Spirig, Shire/Sangamo

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel